Full-Time

Analyst 2 Analytical Monitor

Posted on 8/29/2025

Deadline 12/1/25
Johnson & Johnson

Johnson & Johnson

10,001+ employees

Global healthcare company offering pharma, devices.

No salary listed

High Wycombe, UK

Hybrid

Hybrid role requiring 3 days on-site weekly.

Category
Biology & Biotech (2)
,
Required Skills
Risk Management
Data Analysis
Google Cloud Platform
Requirements
  • Bachelor's degree (e.g., Bachelor of Science, Bachelor of Arts) or equivalent professional experience is required, preferably in Health Sciences or Data Sciences.
  • Advanced degrees preferred (e.g., Master of Science, Doctor of Philosophy).
  • Approximately 4+ years experience in Pharmaceutical, Contract Research Organization or Biotech industry or related field or industry.
  • Knowledge of trial site operations and study execution.
  • Working knowledge of regulatory guidelines (e.g., International Council for Harmonisation - Good Clinical Practice).
  • Demonstrated understanding of data analysis and familiarity with basic statistical concepts.
  • Project, Issue, and risk management experience with ability to apply critical thinking and problem-solving skills, to drive solutions and helping to lead teams to successful outcomes.
  • Experience working with technology platforms and systems used for the collection, analysis and reporting of data.
  • Ability to effectively collaborate in an environment of cross-functional stakeholders, plan and coordinate tasks effectively.
  • Strong ability to communicate effectively (written and verbal).
  • Good written and verbal communications skills (in English).
  • Knowledge of clinical drug development processes.
Responsibilities
  • Conducting activities in compliance with Johnson & Johnson functional Standard Operating Procedures (SOPs), processes and policies.
  • Supporting innovation or process improvement projects which may include but are not limited to requirements development, user acceptance testing and identification of improvements to existing and new analytical tools.
  • Facilitating smooth and effective communication, managing multiple communication streams, and following agreed escalation pathways where needed.
  • Performs analytical monitoring activities for clinical trials within assigned scope of responsibility in line with portfolio timelines and priorities, including support of execution and close-out as outlined in the end-to-end process.
  • Analytical Monitors will conduct regular (fit for purpose) reviews at site and subject level that will help early detection of issues, and prevent recurrence.
  • Collaborates closely with the Site Manager and Central Monitoring Manager to action trends and signals detected at the site and subject level.
  • Accesses various systems, databases and reporting tools to identify potential risks related to the site and subject level data quality, study participant safety and compliance by identifying trends and early warning signals.
  • Provides timely analytical data insights to support the Site Managers in making decisions on site prioritization and critical engagement.
Desired Qualifications
  • Working with complex data structures and reporting specifications.
  • Working with external data e.g., Safety Lab, Pharmacokinetics, Simple Biomarkers, Electrocardiograms, or similar.
  • Proficiency in statistical analysis, data modelling, and data visualization techniques, or demonstrated strong knowledge in these areas.
  • Knowledge of Risk-based Quality Management (RBQM) / Risk-Based Monitoring (RBM) / Quality by Design (QbD) concepts.

Johnson & Johnson operates in three main areas—pharmaceuticals, medical devices, and consumer health products—serving consumers, healthcare professionals, and institutions worldwide. It develops prescription medicines, sells surgical and vision care devices, and offers over-the-counter and personal care products, funded by direct sales, partnerships, and distribution agreements, with heavy investment in research and development. The company differentiates itself by combining three complementary businesses under one umbrella and maintaining a global footprint with an emphasis on science, innovation, and inclusive culture. Its goal is to help people live healthier lives by delivering reliable, high-quality healthcare products and solutions that improve patient outcomes.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Simplify Jobs

Simplify's Take

What believers are saying

  • CARVYKTI and RYBREVANT are driving near-term oncology growth.
  • IMAAVY and CAPLYTA expand J&J into rare immunology and neuropsychiatry.
  • The Firefly Bio acquisition adds a pan-KRAS oncology platform.

What critics are saying

  • STELARA biosimilar erosion is already cutting a major immunology franchise.
  • Firefly Bio's KRAS platform remains early and can fail clinically.
  • AI surgery and Shockwave launches face adoption, reimbursement, and execution risk.

What makes Johnson & Johnson unique

  • J&J focuses on Innovative Medicine and MedTech after spinning off Kenvue in 2023.
  • Its portfolio spans oncology, immunology, neuroscience, cardiovascular, and surgical robotics.
  • The company combines internal R&D with acquisitions like Abiomed, Shockwave, and Ambrx.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Johnson & Johnson who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Remote Work Options

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

-11%

1 year growth

-11%

2 year growth

-10%
Johnson & Johnson
Jun 8th, 2026
Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform

• Expands the Company’s expertise in targeting pan-KRAS and other drivers of hard-to-treat cancers • Acquisition adds a proprietary degrader antibody conjugate platform designed to overcome key limitations of existing therapeutic approaches • Strengthens leadership in next-generation antibody engineering to accelerate oncology innovation

Yahoo Finance
Apr 14th, 2026
J&J's Spravato hits $468M in Q1 sales, signalling upside for psychedelics peers like Atai

Johnson & Johnson's Spravato reported $468 million in first-quarter 2026 sales, up 46% year over year, signalling potential for psychedelics-focused companies like AtaiBeckley Inc., according to Jefferies analysts. The esketamine nasal spray, approved for treatment-resistant depression, is on track to reach an annualised run rate exceeding $1.9 billion. Jefferies maintained that Spravato could hit $3 billion in annual sales by 2027 and $5 billion at peak. Over 200,000 patients have been treated globally, up from 140,000 at the start of 2025. Analysts said Spravato's commercial success demonstrates psychedelics can succeed in mainstream healthcare, with existing treatment infrastructure potentially easing adoption of emerging therapies. They highlighted ATAI's intranasal candidate BPL-003 as fitting seamlessly into Spravato's treatment paradigm.

Yahoo Finance
Apr 14th, 2026
J&J hits $100B milestone with 6.4% growth, eyes double-digit revenue by decade's end

Johnson & Johnson reported 6.4% operational sales growth in Q1 2026, raising full-year guidance to $100.2 billion — the first time the company has reached the $100 billion milestone. The company reaffirmed expectations for double-digit revenue growth by decade's end. Innovative Medicine grew 7.4%, driven by 10 double-digit growing brands including DARZALEX and TREMFYA, despite a 61.7% decline in STELARA due to biosimilar competition. MedTech posted 4.6% growth, led by heart recovery and electrophysiology divisions. The company successfully launched ICOTYDE, the first oral IL-23 peptide for immunology. Management is progressing a $55 billion US manufacturing and R&D investment through 2029, with $12 billion already deployed. The planned separation of its DePuy Synthes Orthopaedics business targets mid-2027 completion.

Business Wire
Apr 7th, 2026
Johnson & Johnson launches VARIPULSE Pro in Europe with 5x faster ablation for atrial fibrillation treatment

Johnson & Johnson has launched VARIPULSE Pro in Europe following CE Mark approval, advancing its pulsed field ablation portfolio for treating atrial fibrillation. The system features a new pulse sequence that operates five times faster than its predecessor whilst maintaining equivalent lesion quality. VARIPULSE Pro integrates with the CARTO 3 mapping system and offers a lower temperature profile whilst preserving the platform's established safety and effectiveness profiles. The company is conducting the VARIPURE multicentre study to generate clinical evidence during the commercial launch phase. The technology addresses atrial fibrillation, the most common cardiac arrhythmia affecting over 50 million people worldwide. Johnson & Johnson will showcase VARIPULSE Pro at the European Heart Rhythm Association annual meeting, with 12-month interim study results to be presented. The device is not currently approved in the United States.

Yahoo Finance
Apr 3rd, 2026
J&J's dividend stays resilient despite market sell-offs and healthcare challenges

Johnson & Johnson has raised $120 million in a Series C round led by Ribbit Capital, valuing the company at $1.45 billion. Sequoia and Kleiner Perkins participated, with Emerson Collective joining as a new backer. The pre-revenue company is developing "Mathematical Superintelligence", an AI system focused on advanced reasoning that claims to eliminate hallucinations by requiring outputs in Lean4 programming language. Its flagship model, Aristotle, achieved top-level performance at the International Mathematical Olympiad in July. Founded in 2023, Harmonic has raised $295 million across three funding rounds in 14 months. The company currently offers Aristotle via a free API and plans to commercialise in safety-critical industries like aerospace and finance.

INACTIVE